Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Refractory or Relapsed Mantle Cell Lymphoma (MCL)

Trial Profile

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Refractory or Relapsed Mantle Cell Lymphoma (MCL)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2018

At a glance

  • Drugs Zanubrutinib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors BeiGene
  • Most Recent Events

    • 01 Dec 2018 Results presented in a BeiGene media release.
    • 01 Dec 2018 According to a BeiGene media release, data from the study were presented at the 60th American Society of Hematology Annual Meeting.
    • 15 Nov 2018 According to BeiGene media release, Center for Drug Evaluation of Chinas National Medical Product Administration (NMPA, formerly known as CFDA) has granted priority review status to the New Drug Applications (NDAs) for zanubrutinib in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top